Thermo Fisher Scientific Partners with the CDC to Accelerate Global Microbial Identification

Thermo Fisher Scientific Partners with the CDC to Accelerate Global Microbial Identification
New software connects public health laboratories with MicrobeNet database to advance infectious disease surveillance

July 16, 2015 07:30 AM Eastern Daylight Time

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher ScientificThrough a successful partnership with the Special Bacteriology Reference Laboratory at the Centers for Disease Control and Prevention (CDC), Thermo Fisher Scientific has developed an advanced software solution that enables global public health laboratories to directly access the CDC's MicrobeNet online virtual reference lab database. Now, researchers can more quickly identify microbial pathogens potentially at the root of global outbreaks without needing to refer to multiple databases by instead utilizing one curated by subject matter experts in the field.

Thermo Fisher's MicrobeBridge software platform is designed to seamlessly connect Sanger sequencing results to the MicrobeNet database. Currently, analyzing sequencing data is fragmented over multiple software packages. MicrobeBridge enables researchers to access more easily the public health information stored in MicrobeNet and informs laboratory-based surveillance and the general understanding of disease outbreaks.

"DNA-based microbial identification has become an invaluable tool for public health scientists to identify and track infectious disease outbreaks," said Dan Didier, director of Public Health at Thermo Fisher Scientific. "Yet data analysis has slowed the ability of public health laboratories to act swiftly. MicrobeBridge overcomes that hurdle and equips researchers with technology that helps them to respond more quickly to pathogens that threaten human health."

MicrobeBridge integrates with all Applied Biosystems Capillary Electrophoresis instruments and automates the assembly and QC of raw Sanger sequencing data into a searchable format in the MicrobeNet database, thus minimizing the effort required to match and positively identify specimens. The company also plans to develop compatible software for Thermo Fisher's next-generation sequencing and mass spectrometry platforms.

"Expanding MicrobeNet will allow public health laboratories anywhere in the world to run sequence-based, phenotypic or eventually other tests and match results against a highly curated database comprised of our unique collection of pathogens," said John R. McQuiston, Ph.D., Team Lead, Special Bacteriology Reference Laboratory, Bacterial Special Pathogens Branch, Division of High-Consequence Pathogens and Pathology at the CDC. "With the addition of MicrobeBridge, researchers and public health laboratories will now be able to easily acquire information on thousands of organisms curated by the pathogen subject matter experts at CDC."

For more information about MicrobeBridge, please contact Dan Didier: [email protected]

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and approximately 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit


Media Contact Information:
Thermo Fisher Scientific
Mauricio Minotta, +1 760-929-2456
[email protected]
Chempetitive Group
Rachel Wallace, +1 978-969-2473
[email protected]

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.